体重指数与接受口服抗凝治疗的亚洲房颤患者临床结局
基于韩国国民健康保险数据库,纳入2015年至2017年43 173例接受口服抗凝药的非瓣膜性房颤新用户,按BMI分类分析临床结局。结果显示BMI每增加5 kg/m2与缺血性卒中、大出血、全因死亡及复合结局风险降低独立相关,而低体重组复合结局风险升高,主要由全因死亡增加驱动。
要点
- BMI每增加5 kg/m2,缺血性卒中、大出血和全因死亡风险均显著降低。
- 低体重(BMI<18.5)患者复合临床结局风险升高,主要由全因死亡增加驱动。
- 非维生素K拮抗剂口服抗凝药与华法林对各BMI组结局影响相似。
核心结论
- 较高BMI独立 associated with 较低缺血性卒中、大出血风险和更好生存。
- 低体重患者全因死亡和复合临床结局风险更高。
- 房颤患者的最佳BMI应通过整合照护路径定义和管理。
研究设计与样本
- 纳入43 173例有BMI信息的非瓣膜性房颤口服抗凝药新用户。
- 按BMI分类:低体重<18.5(3%)、正常18.5至<23(28%)、超重23至<25(24%)、肥胖I 25至<30(39%)、肥胖II ≥30(6%)kg/m2。
主要发现
- BMI每增加5 kg/m2与缺血性卒中风险降低相关(HR 0.891,95%CI 0.801-0.992)。
- BMI每增加5 kg/m2与胃肠道出血住院风险降低相关(HR 0.785,95%CI 0.658-0.937)。
- BMI每增加5 kg/m2与大出血风险降低相关(HR 0.794,95%CI 0.686-0.919)。
- BMI每增加5 kg/m2与全因死亡风险降低相关(HR 0.658,95%CI 0.605-0.716)。
- BMI每增加5 kg/m2与复合临床结局风险降低相关(HR 0.751,95%CI 0.706-0.799),颅内出血无显著关联(HR 0.815,95%CI 0.627-1.061)。
关键数值与推荐
- 低体重组复合临床结局风险升高(HR 1.398,95%CI 1.170-1.671),主要由全因死亡增加驱动。
- 非维生素K拮抗剂口服抗凝药与华法林对各BMI组的临床结局影响相似。
临床怎么用
- 对亚洲房颤口服抗凝患者,低体重(BMI<18.5)提示全因死亡和复合结局风险较高,需加强关注。
- 较高BMI与较低缺血性卒中和大出血风险相关,临床决策中不宜仅凭BMI高而过度限制抗凝。
- 非维生素K拮抗剂口服抗凝药与华法林在不同BMI组间效果相似,可按整体照护路径选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The influence of body mass index (BMI) on clinical outcomes in patients with atrial fibrillation remains controversial, especially among Asians. We aimed to evaluate the association between BMI and clinical outcomes in Asian patients with atrial fibrillation receiving oral anticoagulants. METHODS: Using the Korean National Health Insurance database between January 2015 and December 2017, we identified oral anticoagulant new users among patients with nonvalvular atrial fibrillation who had BMI information. We analyzed ischemic stroke, intracranial hemorrhage, hospitalization for gastrointestinal bleeding, major bleeding, all-cause death, and the composite clinical outcome according to BMI categories. RESULTS: A total of 43 173 patients were included across BMI categories (kg/m2): underweight (<18.5) in 3%, normal (18.5 to <23) in 28%, overweight (23 to <25) in 24%, obese I (25 to <30) in 39%, and obese II (≥30) in 6%. Higher BMI (per 5 kg/m2 increase) was significantly associated with lower risks of ischemic stroke (hazard ratio [HR], 0.891 [95% CI, 0.801-0.992]), hospitalization for gastrointestinal bleeding (HR, 0.785 [95% CI, 0.658-0.937]), major bleeding (HR, 0.794 [95% CI, 0.686-0.919]), all-cause death (HR, 0.658 [95% CI, 0.605-0.716]), and the composite clinical outcome (HR, 0.751 [95% CI, 0.706-0.799]), except for intracranial hemorrhage (HR, 0.815 [95% CI, 0.627-1.061]). The underweight group was associated with an increased risk of composite clinical outcome (HR, 1.398 [95% CI, 1.170-1.671]), mainly driven by an increased risk of all-cause death. The effects of non-vitamin K antagonist oral anticoagulant versus warfarin on clinical outcomes were similar across BMI groups. CONCLUSIONS: Higher BMI was independently associated with a lower risk of ischemic stroke, major bleeding, and better survival. Underweight patients had a higher risk of all-cause death and composite clinical outcome. The optimal BMI for patients with atrial fibrillation should be defined and managed according to an integrated care pathway.
引用
- Lee SR, Choi EK, Jung JH, et al. Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation. Stroke. 2021. PMID: 33423512. doi:10.1161/STROKEAHA.120.030356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。